Hims & Hers Health, co and Weight loss
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...
People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback